The Axi Select programme is only available to clients of AxiTrader Limited. CFDs carry a high risk of investment loss. In our dealings with you, we will act as a principal counterparty to all of your ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

Dr. Natalia Misciattelli, Chief Executive Officer of AAVantgarde said, “We are thrilled to welcome Rasmus Holm-Jorgensen as our new CFO. His deep experience in strategy, finance, and global operations ...

Virtune, a Swedish regulated digital asset manager, is announcing the launch of Virtune Stellar ETP on Nasdaq Stockholm, the largest stock exchange ...

"Collaborating with Sponsor Insight gives us the opportunity to provide our clients with concrete data-driven insights on how strategic partnerships deliver results and most importantly how they can ...

du ’s multinational customers now have access to the alliance’s tier-one operators in Europe and the USA, as well as its wider global network. They will also benefit from FreeMove Alliance ’s ...

Kamux Corporation's Annual Report 2024 has been published on the company’s website at kamux.com  . The Annual Report consists of three sections: Report by the Board of Directors and Financial ...

USD 50 billion commitment includes new state-of-the art research and development (R&D) sites, new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California and an ...

MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a virtual Capital Markets Day for ...

Solar Foods Oyj, press release 24 April 2025 at 11.00 EET. Solar Foods has developed Solein® Shake for daily protein needs. Solar Foods continues to develop product concepts to d ...

Roche, in collaboration with Universitätsklinikum Heidelberg, has developed a Chest Pain Triage algorithm – a CE-marked IVD medical device1 set to transform cardiac care; This ...

Orion Corporation (“Orion”) and Criceto IKM B.V. (“Criceto”) today announced the signing of an exclusive license agreement for the development and commercialization of APORON®, a novel apomorphine ...